Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Pigrel

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Anti-T Lymphocyte Immunoglobulin For Human Use
Anti-T lymphocyte immunoglobulin is a preparation of antibodies that reduces activity of immune T cells to prevent or treat organ transplant rejection.
Clopidogrel Hydrogen Sulfate
Clopidogrel hydrogen sulfate is a substance that helps prevent harmful blood clots by stopping platelets from sticking together.
Porcine

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Agregex
Clopid
Clopidix

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Caen Normandie
Head of hematology service
Caen, France
University Hospital Of Clermont-Ferrand
Professor in the Hematology and cell therapy service
Clermont-Ferrand, France
Assistance Publique Hopitaux De Paris
Lymphoid Hematology Unit
Créteil, France

Sponsor: Xenothera
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.